Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: a randomised, placebo-controlled trial (COLAH)

Davis, Courtney R.; Ruediger, Carlee; Dyer, Kathryn A.; Lester, Susan; Graf, Simone; Kroon, Féline P B; Whittle, Samuel L; Hill, Catherine

doi:10.1016/j.joca.2020.11.002

Cited by 26 publications

(43 citation statements)

References 15 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Colchicine, an anti-inflammatory agent used in gouty arthritis was investigated in 64 adults with symptomatic hand OA. 1 mg colchicine daily for 12 weeks was not effective for reducing pain, swollen joint count or increasing grip strength 35 . Intravenous zoledronic acid, a bisphosphonate used in bone diseases and previously shown to reduce cartilage deterioration in animals by inhibiting subchondral bone resorption was investigated in adults with symptomatic knee OA and subchondral BMLs on MRI (n ¼ 223).…”

Section: Theme 7: Novel Pharmacotherapy Trialsmentioning

confidence: 83%

Osteoarthritis year in review 2021: epidemiology & therapy

Quicke

Conaghan

Corp

et al. 2022

Osteoarthritis and Cartilage

215

120

View full text Add to dashboard Cite

Section: Theme 7: Novel Pharmacotherapy Trialsmentioning

confidence: 83%

Osteoarthritis year in review 2021: epidemiology & therapy

Quicke

Conaghan

Corp

et al. 2022

Osteoarthritis and Cartilage

215

120

View full text Add to dashboard Cite

“…They found that colchicine cannot reduce hand pain recorded on VAS, laboratory examination outcome like C-reactive protein, tender and swollen joint count, and Michigan Hand Questionnaire total, function, and pain scores etc., as no difference was found between colchicine and placebo groups. Thus, the results of Davis et al's [ 27 ] study do not support colchicine for treating symptomatic hand OA.…”

Section: Discussionmentioning

confidence: 96%

“…Besides, only the patient-reported adverse events were directly comparable across the trials. When we performed the systematic literature search again in December, we found that Davis et al's [ 27 ] study reported 64 adult patients (54 females, 10 males) aged 40-80 years old with hand OA were randomized to receive colchicine (0.5 mg twice daily) or matching placebo for 12 weeks. They found that colchicine cannot reduce hand pain recorded on VAS, laboratory examination outcome like C-reactive protein, tender and swollen joint count, and Michigan Hand Questionnaire total, function, and pain scores etc., as no difference was found between colchicine and placebo groups.…”

Section: Discussionmentioning

confidence: 99%

The Evaluation of the Efficacy and Safety of Oral Colchicine in the Treatment of Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Trails

Liu

Wang

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Objective. To evaluate the efficacy and safety of oral colchicine in the treatment for knee OA. Design. Meta-analysis. Data Sources. Embase, PubMed (MEDLINE), the Cochrane Library, and Web of Science from inception to December 12, 2021. Study Selection. RCTs comparing colchicine with placebo for knee OA were included. No language or date restrictions were applied. Two authors abstracted data and determined quality. Outcomes of interest included VAS-pain, WOMAC total index, and patient-reported adverse events. Results. A total of five RCTs including 400 adult patients with OA met the inclusion criteria. The mean age of patients included was 56.05 years (range 21 to 79), and 80.87% were female. There was no difference in VAS-pain (MD -1.49; 95% CI -3.15, 0.17; p = 0.08 ) when compared colchicine group with placebo group. And there was no statistically difference in WOMAC total index (std. MD -0.13; 95% CI -0.64, 0.38; p = 0.61 ) and patient report adverse events (RR 1.23; 95% CI 0.72, 2.11; p = 0.46 ). Conclusion. Colchicine is not currently recommended as a treatment for knee OA but might have insignificant effect. The conclusion is limited due to the variation in assessment indicator among available data. Further RCTs with larger sample size and longer follow-up are needed to confirm the findings.

show abstract

“…Recent randomised studies evaluating known synthetic or biological DMARDs failed to demonstrate efficacy in HOA or EHOA except for corticosteroids, which have a suspensive effect but also have safety concerns 14–18 48. It is time to overcome the old scheme of already used rheumatic drugs and to develop innovative specific therapeutic targets in OA.…”

Section: Discussionmentioning

confidence: 99%

“…Despite its burden and frequency, EHOA lacks effective treatments. Recent trials investigating hydroxychloroquine, colchicine and synthetic or biological disease-modifying antirheumatic drugs (DMARDs) give disappointing results 13–17. A recent study showed that 6 weeks of 10 mg prednisolone per day was superior to placebo for HOA symptoms with inflammatory features, but this finding raises safety issues 18.…”

Section: Introductionmentioning

confidence: 99%

Transcutaneous vagus nerve stimulation in erosive hand osteoarthritis: protocol for the randomised, double-blind, sham-controlled ESTIVAL trial

et al. 2022

View full text Add to dashboard Cite

Introduction Patients with erosive hand osteoarthritis (EHOA) experience pain and inflammation, two features that can be targeted by vagus nerve stimulation using electrical auricular transcutaneous vagus nerve stimulation (tVNS). A pilot study demonstrated the feasibility of the procedure, so we designed a randomised sham-controlled trial to determine the safety and efficacy of tVNS in EHOA. Methods and analysis ESTIVAL Study (Essai randomisé comparant la STImulation auriculaire transcutanée du nerf Vague versus sham stimulation dans l’Arthrose DigitaLe Érosive symptomatique et inflammatoire) is a superiority, randomised, double-blind sham-controlled trial comparing two parallel arms: active and sham tVNSs in a 1:1 ratio. Patients with symptomatic EHOA (score ≥40/100 mm on a visual analogue scale (VAS) for pain of 0–100 mm) and inflammatory EHOA (≥1 clinical and ultrasonography-determined interphalangeal synovitis) are included in 18 hospital centres (17 rheumatology and 1 rehabilitation departments) in France. Active and sham tVNSs use an auricular electrode connected to the Vagustim device, with no electric current delivered in the sham group. Patients undergo stimulation for 20 min/day for 12 weeks. The follow-up visits take place at weeks 4, 8 and 12. The enrolment duration is 2 years and started in April 2021; 156 patients are scheduled to be included. The primary outcome is the difference in self-reported hand pain in the previous 48 hours measured on a VAS of 0–100 mm between baseline and week 12. Secondary outcomes include other pain outcomes, function, quality of life, serum biomarker levels, compliance and tolerance. For a subset of patients, MRI of the hand is performed at baseline and week 12 to compare the change in Outcome Measures in Rheumatology/Hand Osteoarthritis MRI Scoring System subscores. The primary analysis will be performed at the end of the study according to the intent-to-treat principle. Ethics and dissemination Ethics approval was obtained from the institutional review board (Comité de Protection des Personnes, 2020-A02213-36). All participants will be required to provide written informed consent. The findings will be published in peer-reviewed journals. Trial registration number NCT04520516; Pre-results. Protocol version and number V.2 of 11 March 2021.

show abstract

Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: a randomised, placebo-controlled trial (COLAH)

Cited by 26 publications

References 15 publications

Osteoarthritis year in review 2021: epidemiology & therapy

Osteoarthritis year in review 2021: epidemiology & therapy

The Evaluation of the Efficacy and Safety of Oral Colchicine in the Treatment of Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Trails

Transcutaneous vagus nerve stimulation in erosive hand osteoarthritis: protocol for the randomised, double-blind, sham-controlled ESTIVAL trial

Contact Info

Product

Resources

About